An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Trial Profile

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs XOMA 358 (Primary)
  • Indications Hyperinsulinaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms XOMA 358
  • Sponsors XOMA
  • Most Recent Events

    • 04 Apr 2017 Results of part 1 (n=12) assessing safety and efficacy of XOMA 358, presented at The 99th Annual Meeting of the Endocrine Society
    • 02 Feb 2017 Planned number of patients changed from 24 to 20.
    • 02 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top